Palo Alto, CA2 Active Studies

Multiple Sclerosis Clinical Trials in Palo Alto, CA

Find 2 actively recruiting multiple sclerosis clinical trials in Palo Alto, CA. Connect with local research sites and explore new treatment options.

2
Active Trials
2
Sponsors
201
Enrolling

Recruiting Multiple Sclerosis Studies in Palo Alto

About Multiple Sclerosis Clinical Trials in Palo Alto

Multiple sclerosis (MS) is an autoimmune disease where the immune system attacks the protective covering of nerve fibers, causing communication problems between the brain and body. Symptoms vary widely and can include vision problems, fatigue, and mobility issues. Disease-modifying therapies have significantly improved outcomes.

There are currently 2 multiple sclerosis clinical trials recruiting participants in Palo Alto, CA. These studies are seeking a combined 201 participants. Research is being sponsored by National Institute of Allergy and Infectious Diseases (NIAID), Memorial Sloan Kettering Cancer Center. Clinical trial participation is free and participants receive study-related medical care at no cost.

Multiple Sclerosis Clinical Trials in Palo Alto — FAQ

Are there multiple sclerosis clinical trials in Palo Alto?

Yes, there are 2 multiple sclerosis clinical trials currently recruiting in Palo Alto, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Palo Alto?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Palo Alto research site will contact you about next steps.

Are clinical trials in Palo Alto free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Palo Alto studies also compensate for your time and travel.

What multiple sclerosis treatments are being tested?

The 2 active trials in Palo Alto are testing new therapies including novel drugs, biologics, and treatment approaches for multiple sclerosis.

Data updated March 2, 2026 from ClinicalTrials.gov